论文部分内容阅读
为期8周的随机、开放性比较研究。60例T2DM患者被随机分为以诺和灵30R治疗的A组、以诺和锐30治疗的B组和以诺和锐30治疗的C组,A组和B组采用每日早、晚餐前两次皮下注射方案,C组采用每日早、晚餐前及睡前三次皮下注射方案。比较两组患者7个时点血糖、HbA1c、低血糖事件及其他不良事件的差异。结果B组和C组三餐后血糖水平明显低于A组(P<0.05);B组和C组低血糖事件发生次数低于A组(P<0.05);C组空腹血糖明显低于其余两组(P<0.05)。两组HbA1c指标、胰岛素用量及其他不良事件差异无统计学意义(P>0.05)。结论诺和锐30对餐后血糖控制更满意,且低血糖事件发生率减少;睡前加用诺和锐30可较好控制空腹血糖。
A 8-week randomized, open comparison study. Sixty patients with T2DM were randomly divided into A group treated with Novo-30R, B group treated with Novo-Rui-30 and C group treated with Novo-Rui-30. Groups A and B received daily breakfast and dinner Two subcutaneous injection programs, C group daily breakfast, dinner and before going to bed three times subcutaneous injection program. The differences of blood glucose, HbA1c, hypoglycemia and other adverse events were compared between the two groups. Results The postprandial blood glucose levels in groups B and C were significantly lower than those in group A (P <0.05). The incidences of hypoglycaemia in groups B and C were lower than those in group A (P <0.05). The fasting blood glucose of group C was significantly lower than that of group A Two groups (P <0.05). HbA1c index, insulin dosage and other adverse events had no significant difference between the two groups (P> 0.05). Conclusion Novo Rui 30 postprandial glycemic control more satisfied, and the incidence of hypoglycemic events reduced; bedtime plus Novo Rui 30 can better control fasting blood glucose.